If Drug Distributors Can Coordinate Without Anti-Trust Concerns During The Coronavirus Pandemic, What About Generic Manufacturers?
Experts and stakeholders suggest it may help avoid drug shortages, but also indicate the interaction, which in normal times would raise anti-trust concerns, may not be needed, even to fight coronavirus.
You may also be interested in...
FDA Commissioner Hahn says industry needs to work with the agency to establish a link to more detailed supply chain information.
The agency said Cipla’s ANDA met all the requirements for approval, but also that there is increased demand for the products.
In addition to our daily in-depth coverage of key events relating to the COVID-19 pandemic, we’re bringing you a periodic round-up of other developments. This edition covers events at EU and member state level, as well as initiatives by international regulators.